Huaqing Zhimei
A high-tech biotechnology firm specializing in the industrialization of Bio-3D printing and human-engineered extracellular matrix (hEECM) materials for regenerative medicine and medical aesthetics.
- CEO / Founder
- Liu Boxun
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $10.3M
- Latest Round
- Series A
- Key Investors
- Leaguer Capital (力合创投), Shaanxi Financial Holding (陕西金控), Zijing Hongxin (紫荆泓鑫)
Technology & Products
Key Products
["h-EECM (Human Engineered Extracellular Matrix) Raw Materials","Meibiyuan (美泌源) Brand - High-end medical aesthetics line","Qingfu Mima (清肤泌码) - Skin repair and regeneration product","Shiguang Mima (时光泌码) - Anti-aging and tissue filling solution","Automated Bio-3D Printing Systems (proprietary R&D equipment)"]
Technological Advantage
Pioneered the transition from 'printing organs' (long-term research) to 'printing factories' (immediate commercialization), solving the scalability and cost issues of high-purity human-derived bioactive materials.
Differentiation
Value Proposition
Transforms biological cells into 'super factories' using 3D bioprinting to mass-produce human-derived bioactive materials (hEECM) that offer superior safety and natural tissue regeneration compared to synthetic or animal-derived alternatives.
How They Differentiate
Huaqing Zhimei differentiates through its 'Super Cell Factory' model. Unlike competitors who focus on recombinant single-protein collagen (expressed in yeast/E.coli), Huaqing Zhimei uses proprietary Bio-3D printing to create structured environments where human cells secrete a complete 'Human Engineered Extracellular Matrix' (hEECM) containing over 1,000 types of active proteins, achieving 100% bio-homology.
Market & Competition
Target Customers
Medical aesthetics clinics, dermatology hospitals, plastic surgery centers, and pharmaceutical research institutions.
Industry Verticals
["Medical Aesthetics","Regenerative Medicine","Tissue Engineering","Biotechnology"]
Competitors
Giant Biogene (巨子生物); Bloomage Biotech (华熙生物); Trautec (创健医疗); Regenovo (捷诺飞)
Growth & Milestones
Growth Metrics
Operating a 2,000-square-meter GMP-standard production facility in Shenzhen; established the first national industry standard for Extracellular Matrix (ECM) in China.
Major Milestones
["Established the first national industry standard for ECM in China (2023)","Successful launch of the 'Meibiyuan' (美泌源) high-end regenerative aesthetics brand","Completion of a 2,000sqm GMP bioactive material production line in Shenzhen (2024)","Series A funding round of tens of millions of CNY (June 2024)"]
Notable Customers
Class-A Hospitals in China; High-end Medical Aesthetics Clinics; Dermatology Research Institutions